Crispr Therapeutics Ag - Cash and Cash Equivalents As of March 31, 2020, Were $889.7 Million.
Crispr Therapeutics Ag Qtrly Total Collaboration Revenue Was $0.2 Million Versus $0.3 Million.
Crispr Therapeutics Ag Qtrly Basic Loss per Share $1.15).
Crispr Therapeutics Ag - Enrollment Ongoing in Clinical Trials of Ctx001 for Patients With Severe Hemoglobinopathies.
Crispr Therapeutics Ag - Enrollment Ongoing in Clinical Trial of Ctx110, Targeting Cd19+ Malignancies.
Adjusted EPS is expected to be -$1.06
Next Quarter Revenue Guidance is expected to be $3.27 Million
Next Quarter EPS Guidance is expected to be -$1.12
More details on our Analysts Page.